NCT05620641CompletedPhase 3
Ondansetron and Gabapentin in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy
Comparative Clinical Study Among Ondansetron and Gabapentin in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy
Source: ClinicalTrials.gov · Last updated 17 Apr 2025
Brief summary (registry, in English)
The aim of this study is to compare the possible efficacy of ondansetron and gabapentin on postoperative nausea and vomiting in patient with morbid obesity who will undergo laparoscopic sleeve gastrectomy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 11 Nov 2022
- Start date
- 1 Oct 2022
- Primary completion date
- 28 Feb 2025
- Lead sponsor
- Tanta University
- Diseases
- Obesity
- NCT number
- NCT05620641
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 100
- From 1 Oct 2022 to the primary completion date, 28 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with previous procedures for the treatment of obesity.
- Administration of antiemetic medication or systemic corticosteroids within 24 hours before surgery
- Patients who experienced vomiting within 24 hours before surgery.
Other illness
- Patients with psychological or psychiatric disease
- Patients with history of alcohol or drug abuse.
- Patients with hypersensitivity or contraindications to any of the drugs used in this study.
Other
- \- Patients with BMI \>55 kg/m2.
- Pregnant females and lactating women.
Who the study is looking for
- Both male and female patients will be included.
- Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥35 kg/m2 with the presence of comorbidity such as hypertension, arthritis, and diabetes.
- Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥ 40 kg/m2 without comorbidity.
- Patients fit for anesthesia and surgery.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gastrointestinal and Laparoscopic Surgery Unit, General Surgery Department, Tanta University Hospital, Tanta, Egypt Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.